𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Combretastatin A4 phosphate: a novel vascular disrupting agent

✍ Scribed by Nagaiah, Govardhanan; Remick, Scot C

Book ID
111645276
Publisher
Future Medicine
Year
2010
Tongue
English
Weight
437 KB
Volume
6
Category
Article
ISSN
1479-6694

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

p38 MAPK, but not ERK1/2, is critically
p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4
✍ Haitian Quan; Yongping Xu; Liguang Lou πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 739 KB

## Abstract Combretastatin A4 (CA4) is a novel vascular disrupting agent that has promising clinical efficacy because of its ability to inhibit microtubule assembly and subsequently disrupt tumor blood flow. In this study, we demonstrate that mitogen‐activated protein kinases (MAPKs) are critically

The combretastatin derivative (Cderiv),
The combretastatin derivative (Cderiv), a vascular disrupting agent, enables polymeric nanomicelles to accumulate in microtumors
✍ Katsuyoshi Hori; Masamichi Nishihara; Kouichi Shiraishi; Masayuki Yokoyama πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 601 KB

A previous study found almost no leakage of polymeric nanomicelles from vessels in microtumors. If such vessels become leaky, sufficient nanomedicines may be delivered to microtumors and large tumors. To create leaky vessels, a combretastatin derivative (Cderiv), a vascular disrupting agent, was use

Vascular effects dominate solid tumor re
Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
✍ Sarah Jane Lunt; Simon Akerman; Sally A. Hill; Matthew Fisher; Victoria J. Wrigh πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 French βš– 1019 KB

## Abstract Vascular‐targeted therapeutics are increasingly used in the clinic. However, less is known about the direct response of tumor cells to these agents. We have developed a combretastatin‐A‐4‐phosphate (CA4P) resistant variant of SW1222 human colorectal carcinoma cells to examine the relati